Indie Asset Partners LLC reduced its holdings in shares of Pfizer Inc. (NYSE:PFE) by 11.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 23,361 shares of the biopharmaceutical company’s stock after selling 2,873 shares during the period. Pfizer makes up 1.0% of Indie Asset Partners LLC’s investment portfolio, making the stock its 20th largest holding. Indie Asset Partners LLC’s holdings in Pfizer were worth $860,000 as of its most recent SEC filing.
Other institutional investors have also modified their holdings of the company. Kinloch Capital LLC acquired a new stake in shares of Pfizer in the 4th quarter worth $25,000. Penbrook Management LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at about $27,000. Cedar Mountain Advisors LLC lifted its stake in shares of Pfizer by 55.4% in the fourth quarter. Cedar Mountain Advisors LLC now owns 842 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 300 shares during the period. Insight Financial Services acquired a new stake in shares of Pfizer in the fourth quarter valued at about $33,000. Finally, Flagship Private Wealth LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at about $41,000. 67.36% of the stock is currently owned by institutional investors.
PFE has been the subject of several recent analyst reports. DZ Bank reiterated a “buy” rating and issued a $41.00 price objective on shares of Pfizer in a research note on Wednesday, February 3rd. Mizuho reduced their price objective on shares of Pfizer from $44.00 to $42.00 and set a “buy” rating for the company in a research note on Wednesday, February 3rd. SVB Leerink reduced their price objective on shares of Pfizer from $44.00 to $40.00 and set a “market perform” rating for the company in a research note on Wednesday, February 3rd. JPMorgan Chase & Co. set a $36.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a research report on Wednesday, February 3rd. Finally, Zacks Investment Research upgraded shares of Pfizer from a “sell” rating to a “hold” rating and set a $37.00 target price for the company in a research report on Thursday, October 29th. Eleven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Pfizer currently has a consensus rating of “Hold” and a consensus target price of $39.38.
Shares of NYSE PFE traded down $0.51 during midday trading on Tuesday, reaching $33.75. 944,526 shares of the stock were exchanged, compared to its average volume of 35,504,273. The company has a market capitalization of $187.60 billion, a P/E ratio of 22.10, a P/E/G ratio of 2.79 and a beta of 0.70. Pfizer Inc. has a 52-week low of $27.88 and a 52-week high of $43.08. The company has a current ratio of 1.40, a quick ratio of 1.13 and a debt-to-equity ratio of 0.76. The stock has a 50 day moving average price of $35.94 and a 200-day moving average price of $37.10.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 2nd. The biopharmaceutical company reported $0.42 EPS for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.04). The firm had revenue of $11.68 billion for the quarter, compared to analysts’ expectations of $11.32 billion. Pfizer had a return on equity of 24.88% and a net margin of 17.85%. The business’s quarterly revenue was up 11.8% compared to the same quarter last year. During the same quarter last year, the firm earned $0.55 earnings per share. On average, analysts forecast that Pfizer Inc. will post 2.89 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, March 5th. Stockholders of record on Friday, January 29th will be issued a dividend of $0.39 per share. The ex-dividend date is Thursday, January 28th. This is an increase from Pfizer’s previous quarterly dividend of $0.38. This represents a $1.56 dividend on an annualized basis and a dividend yield of 4.62%. Pfizer’s payout ratio is 52.88%.
Pfizer Inc develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands.
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.